Carbonic Anhydrases III and IV Autoantibodies in Rheumatoid Arthritis, Systemic Lupus Erythematosus, Diabetes, Hypertensive Renal Disease, and Heart Failure
Table 4
The cytokine levels of subjects (mean (SD)).
RA
SLE
T1D
T1DN
T2D
T2DN
HTN
HT
IL-6 (ng/L)
control
2.31 (0.63)
2.28 (0.71)
2.39 (0.69)
2.25 (0.67)
2.01 (0.58)
1.97 (0.64)
2.33 (0.59)
2.18 (0.61)
patients
5.02* (1.41)
4.38* (1.64)
2.47 (0.96)
3.05* (1.53)
2.78* (0.88)
2.85* (0.93)
2.58 (1.22)
2.35 (0.97)
IL-17 (ng/L)
control
1.24 (0.21)
1.26 (0.29)
1.36 (0.31)
1.38 (0.27)
1.25 (0.33)
1.33 (0.26)
1.39 (0.40)
1.28 (0.35)
patients
1.96* (0.90)
2.13* (0.75)
1.55 (0.76)
1.97* (0.65)
1.41 (0.57)
1.48 (0.73)
1.27 (0.70)
1.35 (0.55)
TNF-α (ng/L)
control
12.37 (2.45)
11.97 (3.69)
12.39 (3.21)
13.17 (3.39)
12.02 (4.13)
13.39 (3.64)
12.47 (3.68)
12.63 (4.36)
patients
14.65 (6.34)
16.97* (6.93)
13.23 (5.61)
14.37 (8.35)
15.23* (4.32)
16.37* (6.55)
11.95 (4.37)
12.96 (3.37)
IFN-γ (ng/L)
control
11.01
12.25
11.69
12.64
11.64
10.89
11.39
12.43
patients
16.38* (6.36)
14.99* (4.08)
12.06* (4.11)
14.15* (5.62)
12.03 (4.21)
11.59 (3.03)
12.78 (4.32)
13.36 (5.69)
*There were significant differences between patients and control (P < 0.05). HTN: hypertensive nephropathy; HT: heart failure.
